New insights are challenging previously held beliefs about the role of astrocytes in AD, and the astrocyte-derived plasma glial fibrillary acidic protein (GFAP) has been proposed as an early marker of the disease, even in cognitively normal individuals with a normal amyloid-β status [12, 13]. The gene discussed is GFAP; the disease is Alzheimer disease.